ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

MYO Myomo Inc

3.76
-0.16 (-4.08%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Myomo Inc AMEX:MYO AMEX Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.16 -4.08% 3.76 4.19 3.65 3.95 446,405 01:00:00

Myomo To Participate in the 35th Annual Roth Conference

06/03/2023 9:05pm

Business Wire


Myomo (AMEX:MYO)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more Myomo Charts.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that management will presenting at the 35th Annual Roth Conference, March 13-14, 2023 at The Ritz-Carlton, Dana Point, Calif. David Henry, Myomo’s chief financial officer will participate in a “Fireside Chat” on Monday, March 13th at 1:30 p.m. PT and will be available for one-on-one meetings throughout the conference. A live webcast of the presentation will be available here and will also be archived in the Investors section of the Company’s website.

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.

Myomo: ir@myomo.com

LHA Investor Relations: Kim Sutton Golodetz kgolodetz@lhai.com 212-838-3777

1 Year Myomo Chart

1 Year Myomo Chart

1 Month Myomo Chart

1 Month Myomo Chart

Your Recent History

Delayed Upgrade Clock